S

    Scinai Immunotherapeutics Ltd (SCNI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.50
    -0.01 (-0.40%)

    Market Cap: $1.70M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    43%(9/21)
    Avg Surprise
    -598.86%
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    Reported Jul 7
    		$-0.74N/AN/ABeat-117.2%
    Mar 26
    Reported Jun 10
    		$0.94N/AN/ABeat+103.6%
    Sep 25
    Reported Dec 2
    		$-24.85N/AN/ABeat-300.6%
    Jun 25
    Reported Sep 2
    		$-2.60$0.00N/AMiss+39.7%
    Mar 25
    Reported May 7
    		$4.31$0.00N/ABeat+118.0%
    Dec 24
    Reported Feb 26
    		$-26.35N/AN/ABeat+89.0%
    Sep 24
    Reported Nov 22
    		$12.39N/AN/ABeat+54.9%
    Jun 24
    Reported Jul 2
    		$-4.31$0.00N/ABeat+64.1%
    Mar 24
    Reported May 15
    		$-24.00$-6.20-287.10%Miss-100.0%
    Dec 23
    Reported Dec 31
    		$-240.00$-62.00-287.10%Miss-82858.6%
    Sep 23
    Reported Oct 31
    		$8.00$-9.40+185.11%Beat+1411.5%
    Jun 23
    Reported Aug 11
    		$-12.00$-9.10-31.87%Miss+49.9%
    Mar 23
    Reported Apr 17
    		$-12.00$-7.30-64.38%Miss-120100.0%
    Sep 22
    Reported Nov 30
    		$0.29N/A+129.00%Beat+4703.2%
    Jun 22
    Reported Aug 25
    		$-0.61$-1.00+39.00%Beat-6459.1%
    Mar 22
    Reported Jun 1
    		$-23.93$-10.00-139.30%Miss-1999.1%
    Dec 21
    Reported Mar 31
    		$0.01N/A+106.25%Beat-99.7%
    Sep 21
    Reported Nov 30
    		$-0.01N/AN/ABeat-172.4%
    Jun 21
    Reported Aug 26
    		$-0.01N/AN/ABeat+90.7%
    Mar 21
    Reported May 13
    		$-1.14$-0.01-11300.00%Miss+60.3%
    Dec 20
    Reported Mar 31
    		$3.05$-1.00+405.00%Beat+38707.6%
    Sep 20
    Reported Sep 30
    		$0.01N/AN/ABeat+100.6%
    Jun 20
    Reported Aug 20
    		$-0.10$-0.01-900.00%Miss+98.0%
    Mar 20
    Reported Jun 12
    		$-2.87$-1.00-187.00%Miss+26.2%
    Dec 19
    Reported Dec 31
    		$-0.01N/AN/ABeat+41.0%
    Sep 19
    Reported Nov 26
    		$-1.44$-2.00+28.00%Beat-433.3%
    Jun 19
    Reported Aug 28
    		$-5.10$-2.00-155.00%Miss-18445.5%
    Mar 19
    Reported Apr 30
    		$-3.89$-1.00-289.00%Miss-179.9%
    Dec 18
    Reported Dec 31
    		$-0.01N/AN/ABeat+33.0%
    Sep 18
    Reported Nov 13
    		$-0.27N/A+73.00%Beat-102.4%
    Jun 18
    Reported Aug 22
    		$-0.03$-0.01-175.00%Miss+100.0%
    Mar 18
    Reported May 29
    		$-1.39N/AN/ABeat-6920.2%
    Dec 17
    Reported Mar 31
    		$-0.02$0.00N/AMiss-1566.7%
    Sep 17
    Reported Nov 28
    		$11.43$-9.50+220.32%Beat+219707.7%
    Jun 17
    Reported Aug 31
    		$-78.06N/AN/ABeat-
    Mar 17
    Reported May 30
    		$-0.02$-0.01-98.00%Miss-
    Dec 16
    Reported Dec 31
    		$-0.00N/AN/ABeat-
    Sep 16
    Reported Nov 28
    		$0.01$-0.01+152.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio-0.01EV/EBITDA1.13x
    Price/FCF-19.43xFCF Yield-5.15%
    Profitability
    Profit Margin-174.80%Operating Margin-466.50%
    ROE-26.50%ROIC-68.17%
    Financial Health
    Debt/Equity0.03xInterest Coverage-18.16x
    Current Ratio1.56xQuick Ratio1.56x
    Trading Statistics
    Beta2.09Avg Volume546.13K
    52-Week High$16.8052-Week Low$2.15

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.78
    SMA 20$2.62
    SMA 50$2.61
    SMA 200$6.15
    EMA 10$2.69
    EMA 20$2.67
    EMA 50$2.94
    EMA 200$6.99

    MACD

    Line: 0.00Signal: 0.00Hist: 0.00

    ADX

    ADX: 42.0+DI: 9.9-DI: 2.4

    Aroon & PSAR

    Aroon Up76.0
    Aroon Down32.0
    PSAR$0.60

    Bollinger Bands

    Upper Band$3.14
    Lower Band$2.09
    %B Position4040%(Upper)
    Band Width0.39

    RSI (14-Day)

    Neutral
    44.5

    Momentum Oscillators

    Stoch %K69.7
    Stoch %D73.4
    Williams %R-32.1
    ROC (10d)9.6%
    Momentum0.22
    CCI (20d)70.5
    MFI (14d)75.5

    Volatility Measures

    ATR (14d)$1.57(62.7%)
    StdDev (20d)0.26
    Hist Vol102.6%(High)

    Volume Flow

    VWAP$2.54
    OBV172.7M
    AD Line982022782666.7B
    CMF (20d)119.234

    Volume Metrics

    Avg Vol (20d)329.2K
    Vol Ratio0.1x(Low)
    VWMA (20d)$2.75

    Pivot Points

    R3$3.53
    R2$3.26
    R1$2.88
    Pivot Point$2.61
    S1$2.23
    S2$1.96
    S3$1.58

    Advanced Oscillators

    TSI0.71
    Ultimate Osc63.5
    KST66.34

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$467,898$487,674$263,636$269,000$386,500$586,000$206,000$168,000$284,000$0$0$0
    Cost of Revenue$1.74M$1.60M$1.92M$960,000$1.02M$358,000$373,000$417,000$448,000$157,730$84,910$144,531
    Gross Profit$-1,273,498$-1,114,969$-1,382,000$-691,000$-635,000$228,000$-167,000$-249,000$-164,000$-157,730$-84,910$-144,531
    Operating Expenses$909,351$1.35M$1.16M$1.20M$1.25M$1.80M$2.47M$2.17M$-4,119,000$1.93M$1.77M$2.10M
    R&D$214,623$626,297$-103,128$566,000$618,500$1.29M$1.34M$1.41M$1.22M$1.57M$633,795$1.13M
    SG&A$0$721,000$719,451$0$755,000$501,000$759,000$764,000$519,000$484,000$1.21M$968,000
    Operating Income$-2,182,849$-2,460,312$-2,815,515$-1,889,500$-1,881,500$-1,568,000$-2,263,000$-2,420,000$3.96M$-1,928,000$-1,851,856$-2,102,000
    Interest Income$0$0$9,058$0$0$0$14.66M$14.76M$0$0$0$5.21M
    Interest Expense$103,751$111,696$162,558$197,000$185,500$37,000$37,000$1.88M$293,924$231,000$512,495$16,836
    Income Before Tax$-2,037,394$3.57M$-4,173,000$-2,086,500$-2,067,000$-1,557,000$-2,203,000$10.46M$-2,322,000$-2,159,000$-2,355,254$3.11M
    Income Tax Expense$0$0$0$0$0$0$0$0$-1$112,724$40,188$184,586
    Net Income$-2,037,394$3.57M$-2,053,132$-2,086,500$-2,067,000$-1,557,000$-2,230,000$10.46M$-2,322,000$-2,159,000$-2,355,254$3.11M
    EBITDA$-1,586,787$-2,008,540$-3,193,015$-1,531,000$-1,529,500$-1,217,000N/A$12.84M$-1,531,000$-1,772,000$-1,766,946$-1,957,000
    EBIT$-2,182,849$-2,460,312$-3,910,015$-1,889,500$-1,881,500$-1,568,000N/A$12.34M$-2,027,000$-1,928,000$-1,851,856$-2,102,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SCNI

    News

    Scinai Immunotherapeutics Q2 2026 Earnings Call Transcript

    Scinai Immunotherapeutics held its Q2 2026 earnings call, detailing a significant transformation through the acquisition of Recipharm's operations in Yavne, Israel. CEO Amir Reichman highlighted a shift from integration to execution, aiming for approximately $5 million in CDMO revenue for 2026, while emphasizing capital discipline in R&D and strategic financing. The company reported $3.1 million in committed customer orders and a net profit of $1.57 million driven primarily by a non-cash bargain-purchase gain.

    MarketBeat•8/26/26•
    Neutral

    Earnings call transcript: Scinai posts H1 2026 revenue growth as losses persist

    Scinai Immunotherapeutics reported a 22.7% revenue increase in H1 2026, reaching $949,000, driven by its acquisition of Recipharm Israel operations which expanded its CDMO business. Despite this growth, the company still posted an operating loss of $4.6 million and a gross loss of $2.37 million, with a reported net income of $1.57 million primarily due to a non-cash bargain purchase gain. Management aims for $5 million in CDMO revenue for 2026, focusing on execution and converting customer commitments into recognized revenue while maintaining capital discipline.

    Investing.com•8/26/26•
    Neutral

    Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum

    Scinai Immunotherapeutics Ltd. has reported its corporate highlights and financial results for the first half of 2026, showing increased revenues primarily from its CDMO business. The company is seeing significant momentum in its CDMO operations, including an expanded clinical manufacturing program for a U.S.-based biopharmaceutical company, and will host an investor webinar to discuss these developments further. Despite an operating loss, the company reported a net income due to a bargain purchase gain from the acquisition of Recipharm Israel.

    PR Newswire•8/25/26•
    Somewhat-Bullish

    Scinai reports H1 2026 results, announces U.S. customer expansion

    Scinai Immunotherapeutics Ltd. reported its financial results for the first half of 2026, showing an increase in revenues primarily due to acquired operations. The company also announced an expanded clinical manufacturing program with a U.S.-based biopharmaceutical company, receiving $650,000 for the program aimed at supporting an investigational drug product towards IND submission and Phase III development. Scinai reported a net income of approximately $1.6 million, largely attributable to a bargain purchase gain from an acquisition, and scheduled an investor webinar for August 26, 2026.

    Investing.com•8/25/26•
    Somewhat-Bullish

    Scinai Immunotherapeutics (SCNI.US) will release its financial report on August 26.

    Scinai Immunotherapeutics (SCNI.US) is scheduled to release its financial report on August 26. Investors will be anticipating the report for insights into the company's financial performance.

    Moomoo•8/24/26•
    Neutral

    Frequently Asked Questions About SCNI

    Does SCNI pay dividends?
    Scinai Immunotherapeutics Ltd (SCNI) does not currently pay a regular dividend.
    What is SCNI's market cap?
    Scinai Immunotherapeutics Ltd (SCNI) has a market capitalization of $1.70M with a current stock price of $2.50.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In